The disclosure relates to (2S,5R)-5-({ [(3’R,4’S,5’R)-6’’-chloro-4’-(2-chloro-3- fluoropyridin-4-yl)-4,4-dimethyl-2’’-oxo-1’’,2’’-dihydrodispiro[cyclohexane-1,2’-pyrrolidine-3’,3’’-indole]-5’-yl]carbonyl} amino)tetrahydro-2H-pyran-2-carboxylic acid. It also relates to compositions and anticancer agents comprising this compound and their use in treating lung cancer, breast cancer, prostate cancer, colon cancer, acute myeloid leukemia, malignant lymphoma, malignant melanoma, retinoblastoma, neuroblastoma, or sarcoma.